> Detailanzeige
Hehlmann, Rüdiger;
Voskanyan, Astghik;
Lauseker, Michael;
Pfirrmann, Markus;
Kalmanti, Lida;
Rinaldetti, Sebastien;
Kohlbrenner, Katharina;
Haferlach, Claudia;
Schlegelberger, Brigitte;
Fabarius, Alice;
Seifarth, Wolfgang;
Spieß, Birgit;
Wuchter, Patrick;
Krause, Stefan;
Kolb, Hans-Jochem;
Neubauer, Andreas;
Hossfeld, Dieter K.;
Nerl, Christoph;
Gratwohl, Alois;
Baerlocher, Gabriela M.;
Burchert, Andreas;
Brümmendorf, Tim H.;
Hasford, Jörg;
Hochhaus, Andreas;
[...]
High-risk additional chromosomal abnormalities at low blast counts herald death by CML
Teilen
Literatur-
verwaltung
Direktlink
Zur
Merkliste
Lösche von
Merkliste
Per Email teilen
Auf Twitter teilen
Auf Facebook teilen
Per Whatsapp teilen
- Medientyp: E-Artikel
- Titel: High-risk additional chromosomal abnormalities at low blast counts herald death by CML
- Beteiligte: Hehlmann, Rüdiger; Voskanyan, Astghik; Lauseker, Michael; Pfirrmann, Markus; Kalmanti, Lida; Rinaldetti, Sebastien; Kohlbrenner, Katharina; Haferlach, Claudia; Schlegelberger, Brigitte; Fabarius, Alice; Seifarth, Wolfgang; Spieß, Birgit; Wuchter, Patrick; Krause, Stefan; Kolb, Hans-Jochem; Neubauer, Andreas; Hossfeld, Dieter K.; Nerl, Christoph; Gratwohl, Alois; Baerlocher, Gabriela M.; Burchert, Andreas; Brümmendorf, Tim H.; Hasford, Jörg; Hochhaus, Andreas; [...]
-
Erschienen:
Springer Science and Business Media LLC, 2020
- Erschienen in: Leukemia, 34 (2020) 8, Seite 2074-2086
- Sprache: Englisch
- DOI: 10.1038/s41375-020-0826-9
- ISSN: 0887-6924; 1476-5551
- Entstehung:
- Anmerkungen:
- Beschreibung: AbstractBlast crisis is one of the remaining challenges in chronic myeloid leukemia (CML). Whether additional chromosomal abnormalities (ACAs) enable an earlier recognition of imminent blastic proliferation and a timelier change of treatment is unknown. One thousand five hundred and ten imatinib-treated patients with Philadelphia-chromosome-positive (Ph+) CML randomized in CML-study IV were analyzed for ACA/Ph+ and blast increase. By impact on survival, ACAs were grouped into high risk (+8, +Ph, i(17q), +17, +19, +21, 3q26.2, 11q23, −7/7q abnormalities; complex) and low risk (all other). The presence of high- and low-risk ACAs was linked to six cohorts with different blast levels (1%, 5%, 10%, 15%, 20%, and 30%) in a Cox model. One hundred and twenty-three patients displayed ACA/Ph+ (8.1%), 91 were high risk. At low blast levels (1–15%), high-risk ACA showed an increased hazard to die compared to no ACA (ratios: 3.65 in blood; 6.12 in marrow) in contrast to low-risk ACA. No effect was observed at blast levels of 20–30%. Sixty-three patients with high-risk ACA (69%) died (n = 37) or were alive after progression or progression-related transplantation (n = 26). High-risk ACA at low blast counts identify end-phase CML earlier than current diagnostic systems. Mortality was lower with earlier treatment. Cytogenetic monitoring is indicated when signs of progression surface or response to therapy is unsatisfactory.